ABCR  Vol.3 No.3 , July 2014
GP88 (Progranulin) Confers Fulvestrant (Faslodex, ICI 182,780) Resistance to Human Breast Cancer Cells

The 88 kDa glycoprotein known as GP88, Progranulin or PC cell derived growth factor is an autocrine growth factor with a unique cysteine rich motif that is over expressed in breast cancer whereas it is negative in normal mammary epithelial cells. It has been shown to play a major role in estrogen independence, tamoxifen resistance and tumorigenesis of breast cancer cells. In the present study, we investigated the effect of GP88 overexpression on the response of the human breast cancer MCF-7 cells to the pure estrogen receptor antagonist fulvestrant (ICI 182,780). While fulvestrant effectively inhibited cell proliferation of empty vector transfected cells, it had no inhibitory effect on the proliferation of GP88 overexpressing breast cancer cells. Mouse xenograft experiments in athymic ovariectomized nude mice showed that GP88 over expressing cells were fulvestrant resistant in vivo in contrast to low GP88 expressing cells. We show that the ability of fulvestrant to induce apoptosis determined by measuring cleavage of poly (ADP-ribose) polymerase was inhibited by GP88. Anti-apoptotic activity of GP88 was associated with sustained expression of bcl-2 and bcl-xL after fulvestrant treatment. In contrast, fulvestrant was still able to inhibit the ability of estrogen to stimulate ERE-luciferase reporter gene activity as well as vEGF expression in GP88 over expressing MCF-7 cells similarly to control MCF-7 cells. Collectively, our data suggest that GP88 prevents apoptosis induced by faslodex and contributes to antiestrogen resistance in human breast cancer.

Cite this paper
Tangkeangsirisin, W. and Serrero, G. (2014) GP88 (Progranulin) Confers Fulvestrant (Faslodex, ICI 182,780) Resistance to Human Breast Cancer Cells. Advances in Breast Cancer Research, 3, 68-78. doi: 10.4236/abcr.2014.33010.
[1]   Howell, A. (2001) Future Use of Selective Estrogen Receptor Modulators and Aromatase Inhibitors. Clinical Cancer Research, 7, 4402s-4410s; Discussion 11s-12s.

[2]   Cole, M.P., Jones, C.T. and Todd, I.D. (1971) A New Anti-Oestrogenic Agent in Late Breast Cancer. An Early Clinical Appraisal of ICI46474. British Journal of Cancer, 25, 270-275.

[3]   Clarke, R., Skaar, T.C., Bouker, K.B., Davis, N., Lee, Y.R., Welch, J.N. and Leonessa, F. (2001) Molecular and Pharmacological Aspects of Antiestrogen Resistance. The Journal of Steroid Biochemistry and Molecular Biology, 76, 71-84.

[4]   Hu, X.F., Veroni, M., De Luise, M., Wakeling, A., Sutherland, R., Watts, C.K. and Zalcberg, J.R. (1993) Circumvention of Tamoxifen Resistance by the Pure Anti-Estrogen ICI 182,780. International Journal of Cancer, 55, 873-876.

[5]   Morris, C. and Wakeling, A. (2002) Fulvestrant (“Faslodex”)—A New Treatment Option for Patients Progressing on Prior Endocrine Therapy. Endocrine-Related Cancer, 9, 267-276.

[6]   Kellen, J.A. (2001) Raloxifene: Another Selective Estrogen Modulator. In Vivo, 15, 459-460.

[7]   Howell, A., DeFriend, D.J., Robertson, J.F., Blamey, R.W., Anderson, L., Anderson, E., Sutcliffe, F.A. and Walton, P. (1996) Pharmacokinetics, Pharmacological and Anti-Tumour Effects of the Specific Anti-Oestrogen ICI 182780 in Women with Advanced Breast Cancer. British Journal of Cancer, 74, 300-308.

[8]   Howell, A., Robertson, J.F., Quaresma, Albano. J., Aschermannova, A., Mauriac, L., Kleeberg, U.R., Vergote, I., Erikstein, B., Webster, A. and Morris, C. (2002) Fulvestrant, formerly ICI 182,780, Is as Effective as Anastrozole in Postmenopausal Women with Advanced Breast Cancer Progressing after Prior Endocrine Treatment. Journal of Clinical Oncology, 20, 3396-3403.

[9]   Johnston, S.R. (1997) Acquired Tamoxifen Resistance in Human Breast Cancer-Potential Mechanisms and Clinical Implications. Anticancer Drugs, 8, 911-930.

[10]   Foekens, J.A., Peters, H.A., Grebenchtchikov, N., Look, M.P., Meijer-van Gelder, M.E., Geurts-Moespot, A., van der Kwast, T.H., Sweep, C.G. and Klijn, J.G. (2001) High Tumor Levels of Vascular Endothelial Growth Factor Predict Poor Response to Systemic Therapy in Advanced Breast Cancer. Cancer Research, 61, 5407-5414.

[11]   Osborne, C.K., Pippen, J., Jones, S.E., Parker, L.M., Ellis, M., Come, S., Gertler, S.Z., May, J.T., Burton, G., Dimery, I., Webster, A., Morris, C., Elledge, R. and Buzdar, A. (2002) Double-Blind, Randomized Trial Comparing the Efficacy and Tolerability of Fulvestrant versus Anastrozole in Postmenopausal Women with Advanced Breast Cancer Progressing on Prior Endocrine Therapy: Results of a North American Trial. Journal of Clinical Oncology, 20, 3386-3395.

[12]   Johnston, S.R., Saccani-Jotti, G., Smith, I.E., Salter, J., Newby, J., Coppen, M., Ebbs, S.R. and Dowsett, M. (1995) Changes in Estrogen Receptor, Progesterone Receptor, and pS2 Expression in Tamoxifen-Resistant Human Breast Cancer. Cancer Research, 55, 3331-3338.

[13]   McLeskey, S.W., Zhang, L., El-Ashry, D., Trock, B.J., Lopez, C.A., Kharbanda, S., Tobias, C.A., Lorant, L.A., Hannum, R.S., Dickson, R.B. and Kern, F.G. (1998) Tamoxifen-Resistant Fibroblast Growth Factor-Transfected MCF-7 Cells Are Cross-Resistant in Vivo to the Antiestrogen ICI 182,780 and Two Aromatase Inhibitors. Clinical Cancer Research, 4, 697-711.

[14]   Nicholson, R.I., Staka, C., Boyns, F., Hutcheson, I.R. and Gee, J.M.W. (2004) Growth-Factor Driven Mechanisms Associated with Resistance to Estrogen Deprivation in Breast Cancer: New Opportunities for Therapy. Endocrine-Related Cancer, 11, 623-641.

[15]   Carlomagno, C., Perrone, F., Gallo, C., De Laurentiis, M., Lauria, R., Morabito, A., Pettinato, G., Panico, L., D’Antonio, A., Bianco, A.R. and De Placido, S. (1996) c-erb B2 Overexpression Decreases the Benefit of Adjuvant Tamoxifen in Early-Stage Breast Cancer without Axillary Lymph Node Metastases. Journal of Clinical Oncology, 14, 2702-2708.

[16]   Pietras, R.J., Arboleda, J., Reese, D.M., Wongvipat, N., Pegram, M.D., Ramos, L., Gorman, C.M., Parker, M.G., Sliwkowski, M.X. and Slamon, D.J. (1995) HER-2 Tyrosine Kinase Pathway Targets Estrogen Receptor and Promotes Hormone-Independent Growth in Human Breast Cancer Cells. Oncogene, 10, 2435-2446.

[17]   McClelland, R.A., Barrow, D., Madden, T.A., Dutkowski, C.M., Pamment, J., Knowlden, J.M., Gee, J.M. and Nicholson, R.I. (2001) Enhanced Epidermal Growth Factor Receptor Signaling in MCF7 Breast Cancer Cells after Long-Term Culture in the Presence of the Pure Antiestrogen ICI 182,780 (Faslodex). Endocrinology, 142, 2776-2788.

[18]   Okubo, S., Kurebayashi, J., Otsuki, T., Yamamoto, Y., Tanaka, K. and Sonoo, H. (2004) Additive Antitumour Effect of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Gefitinib (Iressa, ZD1839) and the Antioestrogen Fulvestrant (Faslodex, ICI 182,780) in Breast Cancer Cells. British Journal of Cancer, 90, 236-244.

[19]   Cameron, D.A., Keen, J.C., Dixon, J.M., Bellamy, C., Hanby, A., Anderson, T.J. and Miller, W.R. (2000) Effective Tamoxifen Therapy of Breast Cancer Involves Both Antiproliferative and Pro-Apoptotic Changes. European Journal of Cancer, 36, 845-851.

[20]   Zhang, G.J., Kimijima, I., Onda, M., Kanno, M., Sato, H., Watanabe, T., Tsuchiya, A., Abe, R. and Takenoshita, S. (1999) Tamoxifen-Induced Apoptosis in Breast Cancer Cells Relates to Down-Regulation of Bcl-2, but Not Bax and bcl-X(L), without Alteration of p53 Protein Levels. Clinical Cancer Research, 5, 2971-2977.

[21]   Kang, Y., Cortina, R. and Perry, R.R. (1996) Role of c-myc in Tamoxifen-Induced Apoptosis Estrogen-Independent Breast Cancer Cells. Journal of the National Cancer Institute, 88, 279-284.

[22]   Diel, P., Smolnikar, K. and Michna, H. (1999) The Pure Antiestrogen ICI 182780 Is More Effective in the Induction of Apoptosis and Down Regulation of BCL-2 than Tamoxifen in MCF-7 Cells. Breast Cancer Research and Treatment, 58, 87-97.

[23]   Lim, K.B., Ng, C.Y., Ong, C.K., Ong, C.S., Tran, E., Nguyen, T.T., Chan, G.M. and Huynh, H. (2001) Induction of Apoptosis in Mammary Gland by a Pure Anti-Estrogen ICI 182780. Breast Cancer Research and Treatment, 68, 127-138.

[24]   Soma?, S., Chaouat, M., Jacob, D., Perrot, J.Y., Rostène, W., Forgez, P. and Gompel, A. (2003) Antiestrogens Are Pro-Apoptotic in Normal Human Breast Epithelial Cells. International Journal of Cancer, 105, 607-612.

[25]   Clarke, R., Liu, M.C., Bouker, K.B., Gu, Z., Lee, R.Y., Zhu, Y., Skaar, T.C., Gomez, B., O’Brien, K., Wang, Y. and Hilakivi-Clarke, L.A. (2003) Antiestrogen Resistance in Breast Cancer and the Role of Estrogen Receptor Signaling. Oncogene, 22, 7316-7339.

[26]   Bateman, A. and Bennett, H.P. (1998) Granulins: The Structure and Function of an Emerging Family of Growth Factors. Journal of Endocrinology, 158, 145-151.

[27]   Serrero, G. (2003) Autocrine Growth Factor Revisited: PC-Cell-Derived Growth Factor (Progranulin), a Critical Player in Breast Cancer Tumorigenesis. Biochemical and Biophysical Research Communications, 308, 409-413.

[28]   Halper, J. (2010) Growth Factors as Active Participants in Carcinogenesis: A Perspective. Veterinary Pathology, 47, 77-97.

[29]   Lu, R. and Serrero, G. (2001) Mediation of Estrogen Mitogenic Effect in Human Breast Cancer MCF-7 cells by PC-Cell-Derived Growth Factor (PCDGF/Granulin Precursor). Proceedings of the National Academy of Sciences of the United States of America, 98, 142-147.

[30]   Lu, R. and Serrero, G. (2000) Inhibition of PCDGF Expression by Antisense cDNA Transfection Inhibits Tumorigenicity of the Human Breast Carcinoma Cell Line MDA-MB-486. Proceedings of the National Academy of Sciences of the United States of America, 97, 3993-3998.

[31]   Tangkeangsirisin, W., Hayashi, J. and Serrero, G. (2004) PC Cell-Derived Growth Factor Mediates Tamoxifen Resistance and Promotes Tumor Growth of Human Breast Cancer Cells. Cancer Research, 64, 1737-1743.

[32]   Abrhale, T., Brodie, A., Sabnis, G., Macedo, L., Tian, C., Yue, B. and Serrero, G. (2011) GP88 (PC-Cell Derived Growth Factor, Progranulin) Stimulates Proliferation and Confers Letrozole Resistance to Aromatase Overexpressing Breast Cancer Cells. BMC Cancer, 11, 231.

[33]   Serrero, G. and Ioffe, O. (2003) Expression of the PC-Cell Derived Growth Factor in benign and Malignant Human Breast Epithelium. Human Pathology, 34, 1148-1154.

[34]   Serrero, G., Hawkins, D.M., Yue, B., Ioffe, O., Bejarano, P., Phillips, J.T., Head, J.F., Elliott, R.L., Tkaczuk, K.R., Godwin, A.K., Weaver, J.E. and Kim, W. (2012) Progranulin (GP88) Tumor Tissue Expression Is Associated with Increased Risk of Recurrence in Breast Cancer Patients Diagnosed with Estrogen Receptor Positive Invasive Ductal Carcinoma. Breast Cancer Research, 14, R26-R35.

[35]   Tkaczuk, K.R., Yue, B., Zhan, M., Tait, N., Yarlagadda, L., Dai, H. and Serrero, G. (2011) Increased Circulating Level of the Survival Factor GP88 (Progranulin) in the Serum of Breast Cancer Patients When Compared to Healthy Subjects. Breast Cancer Basic and Clinical Research, 5, 155-162.

[36]   Tangkeangsirisin, W. and Serrero, G. (2004) PC Cell-Derived Growth Factor (PCDGF/GP88, Progranulin) Stimulates Migration, Invasiveness and VEGF Expression in Breast Cancer Cells. Carcinogenesis, 25, 1587-1592.

[37]   Lilling, G., Hacohen, H., Nordenberg, J., Livnat, T., Rotter, V. and Sidi, Y. (2000) Differential Sensitivity of MCF-7 and LCC2 Cells, to Multiple Growth Inhibitory Agents: Possible Relation to High bcl-2/Bax Ratio? Cancer Letters, 161, 27-34.

[38]   Takei, H., Lee, E.S. and Jordan, V.C. (2002) In Vitro Regulation of Vascular Endothelial Growth Factor by Estrogens and Antiestrogens in Estrogen-Receptor Positive Breast Cancer. Breast Cancer, 9, 39-42.

[39]   Soares, R., Guo, S., Russo, J. and Schmitt, F. (2003) Role of the Estrogen Antagonist ICI 182,780 in Vessel Assembly and Apoptosis of Endothelial Cells. Ultrastructural Pathology, 27, 33-39.

[40]   He, Z., Ong, C.H., Halper, J. and Bateman, A. (2003) Progranulin Is a Mediator of the Wound Response. Nature Medicine, 9, 225-229.

[41]   Elledge, R.M., Green, S., Pugh, R., Allred, D.C., Clark, G.M., Hill, J., Ravdin, P., Martino, S. and Osborne, C.K. (2000) Estrogen Receptor (ER) and Progesterone Receptor (PgR), by Ligand-Binding Assay Compared with ER, PgR and pS2, by Immuno-Histochemistry in Predicting Response to Tamoxifen in Metastatic Breast Cancer: A Southwest Oncology Group Study. International Journal of Cancer, 89, 111-117.

[42]   Osborne, C.K., Yochmowitz, M.G., Knight 3rd, W.A. and McGuire, W.L. (1980) The Value of Estrogen and Progesterone Receptors in the Treatment of Breast Cancer. Cancer, 46, 2884-2888.

[43]   Luo, L.Y., Diamandis, E.P., Look, M.P., Soosaipillai, A.P. and Foekens, J.A. (2002) Higher Expression of Human Kallikrein 10 in Breast Cancer Tissue Predicts Tamoxifen Resistance. British Journal of Cancer, 86, 1790-1796.

[44]   Berns, E.M., Klijn, J.G., Look, M.P., Grebenchtchikov, N., Vossen, R., Peters, H., Geurts-Moespot, A., Portengen, H., van Staveren, I.L., Meijer-van Gelder, M.E., Bakker, B., Sweep, F.C. and Foekens, J.A. (2003) Combined Vascular Endothelial Growth Factor and TP53 Status Predicts Poor Response to Tamoxifen Therapy in Estrogen Receptor-Positive Advanced Breast Cancer. Clinical Cancer Research, 9, 1253-1258.

[45]   Nicholson, R.I., McClelland, R.A., Gee, J.M., Manning, D.L., Cannon, P., Robertson, J.F., Ellis, I.O. and Blamey, R.W. (1994) Transforming Growth Factor-Alpha and Endocrine Sensitivity in Breast Cancer. Cancer Research, 54, 1684-1689.